Clinical trials: Pulmonary Hypertension Associated With HFpEF, active
Pulmonary Hypertension Associated With HFpEF
Long-Term Open-Label Extension Study of Oral Levosimendan
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with…
- Trial name
- NCT07436689
- Testing
- TNX-103
- Where
- 10 sites in United States
- Volunteers
- 800 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension, Pulmonary Hypertension Associated With HFpEF
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study
this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment…
- Trial name
- NCT07662655
- Testing
- Percutaneous Pulmonary Artery Denervation (PADN), Control group (receiving standard medical therapy alone)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiamen Cardiovascular Hospital, Xiamen University